A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy Delivery
Latest Information Update: 26 Mar 2024
At a glance
- Drugs NBT-NM108 (Primary) ; Irinotecan
- Indications Diarrhoea
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 19 Mar 2024 Planned End Date changed from 1 Sep 2024 to 1 Jul 2025.
- 19 Mar 2024 Planned primary completion date changed from 30 Jan 2024 to 1 Jul 2025.
- 14 Sep 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.